Hospital Infection 'Triples a Patient's Length of Stay'
Posted on: Tuesday, 9 August 2005, 06:00 CDT
A HOSPITAL-acquired infection triples a patient's length of stay and increases their risk of dying five-fold, researchers said yesterday.
A study in the US looked at rates of Staphylococcus aureus (Saureus) infection in hundreds of hospitals to assess the impact on costs, time in hospital and mortality rates.
The researchers concluded that the infections were an enormous burden on hospitals by significantly increasing costs, length of stays for patients and rates of death compared with those without an infection.
S. aureus is a bacterium which frequently lives on the skin or in the nose of a healthy individual.
It can cause illnesses ranging from minor skin infections and abscesses to life-threatening conditions such as pneumonia among patients in hospital.
A growing proportion of S. aureus infections are caused by antibiotic resistant strains such as MRSA (Methicillin Resistant Staphylococcus Aureus).
The rate of MRSA bloodstream infections in English hospitals fell by 6.1% in 2004/05 compared with 2003/04 ( down 472 to a total of 7,212.
The total number of all infections picked up in healthcare settings are said to amount to at least 300,000 a year in England, with an estimated 5,000 deaths and costing the NHS as much as pounds 1bn.
The latest US research, published in Archives of Internal Medicine, found that S. aureus infection was listed as a discharge diagnosis in almost 1% of all hospital stays in the US ( an average of 292,045 stays a year.
The team, from Northwestern Memorial Hospital, calculated that S. aureus infections tripled the average length of stay in hospital ( from 4.5 days to 14.3 days ( compared with stays without an infection.
Source: The Journal - Newcastle-upon-Tyne
Related Articles
- New Epidemic of Sexually Transmitted Hepatitis C Infection in HIV-infected Men in NYC
- Vital New Quality Data on Hospital Readmission Rates Available on Hospital Compare Website
- Cepheid Receives Health Canada License for First On-demand Diagnostic Test for Life-threatening MRSA and S. aureus Infections From Patient Positive Blood Culture Bottles
- Intercell Announces Initiation of Further Phase II Clinical Trial of V710 an Investigational Vaccine to Prevent S. Aureus Infection
- Complications After Cardiac Surgery Increase Hospital Costs, Length of Stay By More Than Two-Thirds
- Alabama Hospitals Compare Infection Prevention Performance Statewide With New Benchmarking Tool
- Sharon surgery postponed due to infection: hospital
- Nabi Biopharmaceuticals Launches New Study to Evaluate StaphVAX(R)'s Ability to Provide Long-Term Protection From S. Aureus Infections in Chronic, High-Risk Patient Groups
- Infected Hospital Shamed
- New Study Demonstrates the Clinical and Economic Challenges of Staphylococcus Aureus Infections
 |
 |
User Comments (0)
RSS Feeds